<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="hwp">casereports</journal-id>
      <journal-id journal-id-type="publisher-id">bmjcasereports</journal-id>
      <journal-title-group>
        <journal-title>BMJ Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1757-790X</issn>
      <publisher>
        <publisher-name>BMJ Publishing Group</publisher-name>
        <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27543609</article-id>
      <article-id pub-id-type="pmc">5015144</article-id>
      <article-id pub-id-type="publisher-id">bcr-2016-216232</article-id>
      <article-id pub-id-type="doi">10.1136/bcr-2016-216232</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
        <subj-group subj-group-type="case-report-type">
          <subject>Images In&#x2026;</subject>
        </subj-group>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>1506</subject>
          <subject>1528</subject>
        </subj-group>
        <subj-group subj-group-type="search-fields">
          <subject>Female</subject>
          <subject>51-70 years</subject>
          <subject>Other Asian</subject>
          <subject>Japan</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Histological transformation from non-small cell to small cell lung carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Haruta(Inoue)</surname>
            <given-names>Yuki</given-names>
          </name>
          <xref ref-type="aff" rid="af1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kataoka</surname>
            <given-names>Yuki</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nikaido</surname>
            <given-names>Junichi</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakajima</surname>
            <given-names>Naoki</given-names>
          </name>
          <xref ref-type="aff" rid="af3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="af1"><label>1</label><institution>Chubu Rosai Byoin</institution>, <addr-line>Nagoya</addr-line>, <country>Japan</country></aff>
      <aff id="af2"><label>2</label><addr-line>Department of Respiratory Medicine</addr-line>, <institution>Hyogo Prefectural Amagasaki General Medical Center</institution>, <addr-line>Amagasaki, Hyogo</addr-line>, <country>Japan</country></aff>
      <aff id="af3"><label>3</label><addr-line>Department of Diagnostic Pathology</addr-line>, <institution>Hyogo Prefectural Amagasaki General Medical Center</institution>, <addr-line>Amagasaki, Hyogo</addr-line>, <country>Japan</country></aff>
      <author-notes>
        <corresp><label>Correspondence to</label> Dr Yuki Haruta(Inoue), <email>gamann92@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>2016</volume>
      <elocation-id>bcr2016216232</elocation-id>
      <history>
        <date date-type="accepted">
          <day>21</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>2016 BMJ Publishing Group Ltd</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="bcr-2016-216232.pdf"/>
      <custom-meta-group>
        <custom-meta>
          <meta-name>special-feature</meta-name>
          <meta-value>unlocked</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Description</title>
      <p>A 58-year-old woman with no history of smoking was admitted to our hospital with exacerbation of cough. CT of the chest revealed a left upper lobe lung tumour. Bronchoscopic biopsy of the tumour revealed stage IV poorly differentiated adenocarcinoma (<xref ref-type="fig" rid="BCR2016216232F1">figure 1</xref>) with epidermal growth factor receptor (EGFR) gene mutation (L858R point mutation). After cytotoxic chemotherapy (cisplatin and pemetrexed) as first-line therapy, disease progression was identified. For the next 3&#x2005;years, she was treated with erlotinib, an EGFR tyrosine kinase inhibitor (TKI). Regimens were changed several times (cisplatin, gemcitabine, docetaxel and afatinib) due to disease progression or adverse effects. After 2&#x2005;months with afatinib, disease progression was again noted. We once again performed bronchoscopic biopsy of the primary tumour, and small cell lung cancer (SCLC) was confirmed from histopathological examination (<xref ref-type="fig" rid="BCR2016216232F2">figures 2</xref><xref ref-type="fig" rid="BCR2016216232F3"/>&#x2013;<xref ref-type="fig" rid="BCR2016216232F4">4</xref>). Levels of tumour markers such as progastrin-releasing peptide and non-specific elastase were elevated. Moreover, a second examination again detected the EGFR gene mutation (L858R point mutation without T790M point mutation). Amrubicin was administered, resulting in radiologically stable disease. Most cases of acquired resistance to EGFR-TKI arise from the emergence of T790M mutation, and morphological transformation to SCLC is rare.<xref rid="R1" ref-type="bibr">1</xref> After the failure of EGFR-TKI, rebiopsy of the tumour is warranted to determine the next treatment strategy.</p>
      <fig id="BCR2016216232F1" orientation="portrait" position="float">
        <label>Figure&#xA0;1</label>
        <caption>
          <p>H&amp;E staining.</p>
        </caption>
        <graphic xlink:href="bcr2016216232f01"/>
      </fig>
      <fig id="BCR2016216232F2" orientation="portrait" position="float">
        <label>Figure&#xA0;2</label>
        <caption>
          <p>H&amp;E staining.</p>
        </caption>
        <graphic xlink:href="bcr2016216232f02"/>
      </fig>
      <fig id="BCR2016216232F3" orientation="portrait" position="float">
        <label>Figure&#xA0;3</label>
        <caption>
          <p>Chromogranin A staining.</p>
        </caption>
        <graphic xlink:href="bcr2016216232f03"/>
      </fig>
      <fig id="BCR2016216232F4" orientation="portrait" position="float">
        <label>Figure&#xA0;4</label>
        <caption>
          <p>Synaptophysin staining.</p>
        </caption>
        <graphic xlink:href="bcr2016216232f04"/>
      </fig>
      <boxed-text position="float" orientation="portrait">
        <caption>
          <title>Learning points</title>
        </caption>
        <list list-type="bullet">
          <list-item>
            <p>After the failure of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), rebiopsy of the tumour should be performed to determine the next treatment strategy.</p>
          </list-item>
          <list-item>
            <p>But it is unclear when to perform rebiopsy after EGFR-TKI failure.</p>
          </list-item>
        </list>
      </boxed-text>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Contributors:</bold> YH, JN and NN participated in patient care. YH wrote the manuscript and YK revised it.</p>
      </fn>
      <fn>
        <p><bold>Competing interests:</bold> None declared.</p>
      </fn>
      <fn>
        <p><bold>Patient consent:</bold> Obtained.</p>
      </fn>
      <fn>
        <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Reference</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortot</surname><given-names>AB</given-names></name>, <name><surname>J&#xE4;nne</surname><given-names>PA</given-names></name></person-group>
<article-title>Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas</article-title>. <source>Eur Respir Rev</source>
<year>2014</year>;<volume>23</volume>:<fpage>356</fpage>&#x2013;<lpage>66</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09059180.00004614">doi:10.1183/09059180.00004614</ext-link><pub-id pub-id-type="pmid">25176972</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
